A Phase 3 interventional study of Teduglutide in Short Bowel Syndrome, sponsored by Shire. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-10.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 11th largest by enrollment, is the only one that started in 2012, is one of 16 in phase 3, and was the 6th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 4 mo–17 yrs
By country, each count listing its studies:
teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2012.
This study's enrollment of 14 is below the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 20 across the 20 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
26 studies in Short Bowel Syndrome by Takeda: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 16 (70%) have results posted.
Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the 10th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2012, is one of 17 in phase 3, and was the 6th registered.
Takeda’s Short Bowel Syndrome studies by the year they started, since 2004.
1 of the studies testing teduglutide in Short Bowel Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Short Bowel Syndrome:
This tab as a report to print or save as PDF → With an account.
This study is a 1-year open label extension study to collect long term efficacy and safety data from patients who have completed approximately 2 years of dosing in Study CL0600-021.
This study served as a 1-year extension study for those US patients who have completed the CL0600-021 study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At completion of Study CL0600-021, subjects will be invited to participate in this trial if they meet the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.05 mg/kg/day
Drug: Teduglutide
0.05 mg/kg/day subcutaneously taken once per day for 12 months
Also known as: Gattex
Summary of Treatment-emergent Adverse Events
As the primary intent of this study was to collect additional safety data, this outcomes measure will provide a summary of the treatment emergent adverse events. Based on the start date of each subject in this study and the study end date, not all subjects reached 12 months.
Time frame: 12 months
This was a 1-year, open-label, multi-center study in subjects who completed Study CL0600-021 (NCT00930644) at any US site.
| Milestone | TED/TED | NT/PBO,TED |
|---|---|---|
| Started | 5 | 9 |
| Completed | 5 | 8 |
| Not completed | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
As the primary intent of this study was to collect additional safety data, this outcomes measure will provide a summary of the treatment emergent adverse events. Based on the start date of each subject in this study and the study end date, not all subjects reached 12 months.
| participants | NT,PBO/TED | TED/TED |
|---|---|---|
| Summary of Treatment-emergent Adverse Events | 4 | 5 |
Collected over 1 year, 2 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NT/PBO,TED | — | 1/9 (11.1%) | 4/9 (44.4%) |
| TED/TED | — | 5/5 (100%) | 4/5 (80%) |
| Event | NT/PBO,TED | TED/TED |
|---|---|---|
| Atrial fibrillationCardiac disorders | 0/9 | 1/5 |
| Atrial tachycardiaCardiac disorders | 0/9 | 1/5 |
| Cardiac failure acuteCardiac disorders | 0/9 | 1/5 |
| Cardiac failure congestiveCardiac disorders | 0/9 | 1/5 |
| CardiomyopathyCardiac disorders | 0/9 | 1/5 |
| Ischaemic cardiomyopathyCardiac disorders | 0/9 | 1/5 |
| Central line infectionInfections and infestations | 0/9 | 1/5 |
| PneumoniaInfections and infestations | 0/9 | 1/5 |
| Urinary tract infectionInfections and infestations | 0/9 | 1/5 |
| In-stent arterial restenosisInjury, poisoning and procedural complications | 0/9 | 1/5 |
| Event | NT/PBO,TED | TED/TED |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/9 | 2/5 |
| Catheter sepsisInfections and infestations | 0/9 | 2/5 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/9 | 2/5 |
| Weight decreasedInvestigations | 0/9 | 2/5 |
| Asthenic conditionsGeneral disorders | 2/9 | 1/5 |
| Abdominal painGastrointestinal disorders | 2/9 | 0/5 |
| Benign neoplasms gastrointestinalNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/9 | 0/5 |
| Cognition and attention disorders and disturbancesPsychiatric disorders | 2/9 | 0/5 |
| HypersensitivityImmune system disorders | 2/9 | 0/5 |
| Viral infectionInfections and infestations | 2/9 | 0/5 |
| Age, Customized(Participants) | TED/TED | NT/PBO,TED | Total |
|---|---|---|---|
| < 45 years | 1 | 2 | 3 |
| 45 - < 65 years | 3 | 6 | 9 |
| >=65 years | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | TED/TED | NT/PBO,TED | Total |
|---|---|---|---|
| Female | 4 | 6 | 10 |
| Male | 1 | 3 | 4 |
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2012 to primary completion in Jul 2013, 14 months.
Results were first posted in Dec 2014, 1 year 5 months after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 14 months is below that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide